Evidence map›Paper›PMID 36304744›Full record

ArticleFrontiers in chemistry2022

Discovery of putative inhibitors against main drivers of SARS-CoV-2 infection: Insight from quantum mechanical evaluation and molecular modeling.

Toheeb A Balogun, Onyeka S Chukwudozie, Uchechukwu C Ogbodo, Idris O Junaid, Olugbodi A Sunday, Oluwasegun M Ige, Abdullahi T Aborode, Abiola D Akintayo, Emmanuel A Oluwarotimi, Isaac O Oluwafemi and 13 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 10 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 18 institutions in 7 countries.

Toheeb A BalogunDepartment of Biochemistry, Adekunle Ajasin University, Akungba-Akoko, Nigeria.
Onyeka S ChukwudozieDepartment of Biological Sciences, University of California, San Diego, San Diego, CA, United States.
Uchechukwu C OgbodoDepartment of Applied Biochemistry, Nnamdi Azikiwe University, Awka, Nigeria.
Idris O JunaidDepartment of Chemistry and Chemical Biology, Stevens Institute of Technology, Hoboken, NJ, United States.
Olugbodi A SundayDepartment of Environmental Toxicology, Universitat Duisburg-Essen, Essen, Germany.
Oluwasegun M IgeDepartment of Marine Biological Resources, Ghent University, Ghent, Belgium.
Abdullahi T AborodeDepartment of Chemistry, Mississippi State University, Starkville, MS, United States.
Abiola D AkintayoDepartment of Chemistry, University of Texas at Dallas, Richardson, TX, United States.
Emmanuel A OluwarotimiDepartment of Chemistry, Missouri University of Science and Technology, Rolla, MO, United States.
Isaac O OluwafemiDepartment of Chemistry, Adekunle Ajasin University, Akungba-Akoko, Nigeria.
Oluwatosin A SaibuDepartment of Environmental Toxicology, Universitat Duisburg-Essen, Essen, Germany.
Prosper ChuckwuemakaDepartment of Biotechnology, Federal University of Technology Akure, Akure, Nigeria.
Damilola A OmoboyowaDepartment of Biochemistry, Adekunle Ajasin University, Akungba-Akoko, Nigeria.
Abdullahi O AlausaDepartment of Biochemistry, Ladoke Akintola University, Ogbomoso, Nigeria.
Nkechi H AtasieClinical Pharmacy Department, Nigeria Correctional Service, Enugu Custodial Centre, Enugu, Nigeria.
Ayooluwa IlesanmiDepartment of Chemistry, Mississipi University for Women Columbus, Columbus, United States.
Gbenga DairoDepartment of Biological Sciences, Western Illinois University, Macomb, IL, United States.
Zainab A TiamiyuDepartment of Biochemistry and Molecular Biology, Federal University Dutsin-ma, Dutsin-Ma, Nigeria.
Gaber E BatihaDepartment of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, Egypt.
Afrah Fahad AlkhurijiDepartment of Zoology, College of Science, King Saud University, Riyadh, Saudi Arabia.
Wafa Abdullah I Al-MegrinDepartment of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia.
Michel De WaardSmartox Biotechnology, Saint-Egréve, France.
Jean-Marc SabatierInstitut de Neurophysiopathologie (INP), Faculté des Sciences Médicales et Paramédicales, Aix-Marseille Université, CNRS UMR 7051, Marseille, France.
Adekunle Ajasin University · NGUniversity of Duisburg-Essen · DECentre National de la Recherche Scientifique · FRDamanhour University · EGFederal University Dutsin-MaFederal University of Technology · NGGhent University · BEInstitut du Thorax · FRKing Saud University · SALadoke Akintola University of Technology · NGMississippi State University · USMissouri University of Science and Technology · USNnamdi Azikiwe University · NGPrincess Nourah bint Abdulrahman University · SAStevens Institute of Technology · USThe University of Texas at Dallas · USUniversity of California, San Diego · USWestern Illinois University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

SARS-CoV-2 triggered a worldwide medical crisis, affecting the world's social, emotional, physical, and economic equilibrium. However, treatment choices and targets for finding a solution to COVID-19's threat are becoming limited. A viable approach to combating the threat of COVID-19 is by unraveling newer pharmacological and therapeutic targets pertinent in the viral survival and adaptive mechanisms within the host biological milieu which in turn provides the opportunity to discover promising inhibitors against COVID-19. Therefore, using high-throughput virtual screening, manually curated compounds library from some medicinal plants were screened against four main drivers of SARS-CoV-2 (spike glycoprotein, PLpro, 3CLpro, and RdRp). In addition, molecular docking, Prime MM/GBSA (molecular mechanics/generalized Born surface area) analysis, molecular dynamics (MD) simulation, and drug-likeness screening were performed to identify potential phytodrugs candidates for COVID-19 treatment. In support of these approaches, we used a series of computational modeling approaches to develop therapeutic agents against COVID-19. Out of the screened compounds against the selected SARS-CoV-2 therapeutic targets, only compounds with no violations of Lipinski's rule of five and high binding affinity were considered as potential anti-COVID-19 drugs. However, lonchocarpol A, diplacol, and broussonol E (lead compounds) were recorded as the best compounds that satisfied this requirement, and they demonstrated their highest binding affinity against 3CLpro. Therefore, the 3CLpro target and the three lead compounds were selected for further analysis. Through protein-ligand mapping and interaction profiling, the three lead compounds formed essential interactions such as hydrogen bonds and hydrophobic interactions with amino acid residues at the binding pocket of 3CLpro. The key amino acid residues at the 3CLpro active site participating in the hydrophobic and polar inter/intra molecular interaction were TYR54, PRO52, CYS44, MET49, MET165, CYS145, HIS41, THR26, THR25, GLN189, and THR190. The compounds demonstrated stable protein-ligand complexes in the active site of the target (3CLpro) over a 100 ns simulation period with stable protein-ligand trajectories. Drug-likeness screening shows that the compounds are druggable molecules, and the toxicity descriptors established that the compounds demonstrated a good biosafety profile. Furthermore, the compounds were chemically reactive with promising molecular electron potential properties. Collectively, we propose that the discovered lead compounds may open the way for establishing phytodrugs to manage COVID-19 pandemics and new chemical libraries to prevent COVID-19 entry into the host based on the findings of this computational investigation.

Indexed as

3CLproCOVID-19glycoproteinmolecular modelingPLproRNA-dependent RNA polymerase (RdRp)SARS-CoV-2

Identifiers

PMID36304744
PMCPMC9593047
OpenAlexW4304183723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.